By binding to respiratory syncytial virus (
RSV),
Synagis® (
palivizumab) can help prevent the virus from multiplying. However, Synagis is not a vaccine, and it does not prevent an RSV infection. Instead, it prevents an infection from becoming severe enough to cause serious complications.
This prescription medicine is not approved for use in adults and is usually given to infants and children age 24 months and younger. It is specifically designed for children who have a high risk for complications with RSV. This includes children who are premature or who have certain types of lung or
heart disease.
Synagis is given as an injection into a muscle once a month during RSV season, which is usually from November to April.
(For more details, click Synagis Uses. This Web page explains why Synagis is not a vaccine and takes a closer look at how this drug works for preventing serious complications from RSV.)
HealthSavvy Sign In
|